No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Chemicals - Specialty
Boai NKY Medical Holdings Ltd. is an international enterprise specializing in the development, production, and global distribution of polyvinylpyrrolidone (PVP) series products. Its extensive product portfolio features pharmaceutical excipients such as Povidone, Crospovidone, and Copovidone, marketed under the KoVidone and PolyKoVidone brand lines. The company also manufactures OraRez PVM/MA copolymers and their derivatives, which are specialized functional polymers vital for bioadhesive and mucoadhesive applications. Additionally, it supplies KoVidone-1, a broad-spectrum agent with biocidal, antifungal, and antiviral efficacy. Further offerings encompass a wide array of chemical solutions, including pharmaceutical solvents, intermediates, various polymers, and vinyl and vinyl ether compounds. Specific branded products like PolyViscol, KoVidone I, WhiVidone, and PVPP are also part of their catalog. These diverse chemical components find integral application across numerous industries, including pharmaceuticals, industrial processes, oral care products, cosmetics, and the food and beverage sector. Founded in Heping, China, in 1987, the company was initially known as Boai NKY Pharmaceuticals Ltd. It transitioned to its current designation, Boai NKY Medical Holdings Ltd., in March 2016.
www.boai-nky.comNo one on the platform currently holds 300109.SZ.
No tracked institution reports a position in 300109.SZ as of their last filing.
No one on the platform has traded 300109.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.7% | — | — | — | ||
| Rev. Growth % | -26.7% | 3.8% | ||||
| Profit Margin % | 16.1% | 21.1% | 17.5% | |||
| Free Cash Flow Margin % | 10.0% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.7B | +8.7% | $0.68 | $0.68–$0.68 | — | 1 |
| 2027 | $1.8B | +10.2% | $0.85 | $0.85–$0.85 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $0.09 | $0.06 | -30.9% |
| 2026-04-23 | $0.11 | $0.13 | +21.8% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300109.SZBoai NKY Medical Holdings Ltd. | $12.95 | +2.05% | $7.5B | — |
| 000566.SZHainan Haiyao Co., Ltd. | $4.52 | -0.66% | $5.9B | — |
| 000597.SZNortheast Pharmaceutical Group Co., Ltd. | $4.63 | +0.22% | $6.6B | — |
| 000908.SZHunan Jingfeng Pharmaceutical Co.,Ltd. | $6.10 | -0.33% | $10.7B | — |
| 000915.SZShandong Wit Dyne Health Co.,Ltd. |
| $24.14 |
| -0.45% |
| $5.7B |
| — |
| 002437.SZHarbin Gloria Pharmaceuticals Co., Ltd | $3.39 | +0.00% | $7.6B | — |
| 002940.SZZhejiang AngLiKang Pharmaceutical CO.,LTD. | $22.82 | +0.40% | $4.5B | — |
Source: Financial Modeling Prep · peers by sector/industry